RxDoctor Payments Data

Rachel Lucente

Family · Staten Island, NYNPI 1346706801

Payments from drug & device makers

$1,668in general payments, 2019–2025

Across 25 payments — averaging $66.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$364
  • AstraZeneca$246
  • Gilead$228
  • Genentech USA, Inc.$150
  • Otsuka America Pharmaceutical, Inc.$142
  • Ultragenyx Pharmaceutical Inc.$125
  • plus $413 from 7 others

What the payments were for

  • Food & beverage$1,668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,668 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$196,845
Medicare patients
231
Services billed
3,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$124,955
RexultiBrexpiprazole48$67,662
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$26,272
JardianceEmpagliflozin28$25,471
XareltoRivaroxaban22$19,529
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$14,876
JanuviaSitagliptin Phosphate11$10,454
GemtesaVibegron12$6,048
Lacosamide15$2,506
Memantine Hcl39$2,077
Duloxetine Hcl32$1,932
Albuterol Sulfate HfaAlbuterol Sulfate44$1,787
Ranolazine ErRanolazine17$1,751
Levothyroxine Sodium152$1,595
Atorvastatin Calcium169$1,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$124,955117 claims
Otsuka America Pharmaceutical, Inc.Rexulti$142$67,66248 claims
GSKTrelegy Ellipta$35$26,27229 claims
Boehringer IngelheimJardiance$125$25,47128 claims
AstraZenecaBreztri Aerosphere$246$14,87617 claims
AbbVieSynthroid$364$1,32029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →